This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants have not had prior targeted therapy. The goal is to see how well the drug controls the cancer and to understand why resistance may…
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Apr 29, 2026 02:39 UTC